Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Co.'s primary product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for ACI. ANEB-001 is an orally bioavailable absorbed treatment. Co.'s proprietary position in the treatment of ACI is protected by an issued patent and rights to a patent application covering various methods of use of the compound and delivery systems. The ANEB stock yearly return is shown above.
The yearly return on the ANEB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANEB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|